Vanda Pharmaceuticals Inc. logo VNDA - Vanda Pharmaceuticals Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 13
HOLD 5
SELL 1
STRONG
SELL 0
| PRICE TARGET: $15.50 DETAILS
HIGH: $21.00
LOW: $10.00
MEDIAN: $15.50
CONSENSUS: $15.50
UPSIDE: 271.70%

Stock News

Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program

Vanda Pharmaceuticals Provides Update on VQW-765 Clinical Development Program

Phase III clinical study of VQW-765 in adults with social anxiety disorder did not meet its primary endpoint Consistent with prior studies, VQW-765 was safe and well tolerated WASHINGTON, Oct. 14, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its clinical development program for VQW-765, a novel small molecule alpha 7 nicotinic acetylcholine receptor (α7-nAChR) partial agonist. Vanda's Phase III clinical study, VP-VQW-765-3201 (Study 3201), which evaluated VQW-765 for the on-demand treatment of acute anxiety in adults with social anxiety disorder, did not meet its primary endpoint.

Oct 14, 2026 01:00 PM • prnewswire.com
Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Rating Reaffirmed as “Buy” by HC Wainwright

Vanda Pharmaceuticals (NASDAQ:VNDA) Stock Rating Reaffirmed as “Buy” by HC Wainwright

Vanda Pharmaceuticals (NASDAQ: VNDA - Get Free Report)'s stock had its "buy" rating reiterated by stock analysts at HC Wainwright in a research report issued to clients and investors on Monday, Marketbeat Ratings reports. They currently have a $20.00 price target on the biopharmaceutical company's stock. HC Wainwright's target price points to a potential upside of

Oct 05, 2026 04:07 AM • defenseworld.net
Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting

Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting

WASHINGTON, Oct. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced participation at the European Academy of Dermatology and Venereology (EADV) Annual Meeting, being held in Vienna, Austria, from September 30 through October 3, 2026. The following will be presented: Presentation Title: "Rapid reduction in neutrophils and neutrophil percentage-to-albumin ratio upon treatment with imsidolimab in patients with GPP" Abstract ID: AS-4323 Poster Number: P1769 Presentation Title: "Immunogenicity of Imsidolimab for the Treatment of Generalized Pustular Psoriasis (GPP)" Abstract ID: AS-2420 Poster Number: P1784 Presentation Title: "Imsidolimab Improves Generalized Pustular Psoriasis (GPP) Pustulation as Measured by the Pustulation Rating Scale (PRS): Results from the GEMINI-1 Study" Abstract ID: AS-2421 Poster Number: P2806 About Imsidolimab Imsidolimab is a fully humanized IgG4 monoclonal antibody that inhibits IL-36 receptor signaling and is being developed for GPP, a rare orphan indication.

Oct 02, 2026 05:06 AM • prnewswire.com
Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder

Vanda Pharmaceuticals Announces Positive Phase III Results for HETLIOZ®(tasimelteon) in Delayed Sleep-Wake Phase Disorder

Study met its primary endpoint: timing of sleep onset shifted 37.1 minutes earlier versus placebo (p=0.022) 60% of HETLIOZ ® treated participants shifted sleep at least 30 minutes earlier, compared to 15% of the placebo arm WASHINGTON, Sept. 29, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced positive topline results from its pivotal Phase III study of HETLIOZ® (tasimelteon) 20 mg in adults with Delayed Sleep-Wake Phase Disorder (DSWPD).

Sep 29, 2026 02:45 PM • prnewswire.com
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission

Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission

WASHINGTON, Aug. 24, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the European Commission, based on the positive opinion received from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, chronic, and potentially life-threatening inflammatory skin disease driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.1 The US Food and Drug Administration (FDA) and Japan's Ministry of Health, Labour and Welfare have previously granted Orphan Drug Designation to imsidolimab for the treatment of GPP. This marks the first time the European Commission has granted orphan designation recognition for a drug to treat GPP in the European Union (EU).

Aug 24, 2026 03:00 AM • prnewswire.com
Arrowstreet Capital Limited Partnership Buys New Position in Vanda Pharmaceuticals Inc. $VNDA

Arrowstreet Capital Limited Partnership Buys New Position in Vanda Pharmaceuticals Inc. $VNDA

Arrowstreet Capital Limited Partnership purchased a new stake in Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 241,430 shares of the biopharmaceutical company's stock, valued at approximately $1,668,000. Arrowstreet Capital Limited Partnership owned approximately

Aug 05, 2026 11:47 PM • defenseworld.net
Vanda Pharmaceuticals Q2 Earnings Call Highlights

Vanda Pharmaceuticals Q2 Earnings Call Highlights

Vanda Pharmaceuticals NASDAQ: VNDA reported second-quarter 2026 revenue of $50.5 million, down 4% from a year earlier, as growth in Fanapt and PONVORY was offset by lower HETLIOZ sales amid generic competition and shipment timing. The company reiterated its full-year revenue outlook and said it expects operating expenses to begin declining late this year, with more substantial reductions anticipated in 2027.

Aug 05, 2026 11:04 PM • marketbeat.com
Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results

Vanda Pharmaceuticals Reports Second Quarter 2026 Financial Results

Fanapt® Q2 2026 net product sales increased 23% to $36.0 million; total prescriptions increased 31%  Full-year 2026 total revenue guidance of $240-$290 million  Cash totaled $170.0 million as of June 30, 2026; expected to fund operations through at least the end of 2027  BYSANTI™ (milsaperidone) received FDA approval for bipolar I disorder and schizophrenia in Q1 2026; commercial launch expected in second half of 2026  Quimilza™ (imsidolimab) BLA for GPP under review by the FDA; PDUFA target action date of December 12, 2026  NEREUS™ for prevention of vomiting induced by motion became commercially available in Q2 2026  Results for three Phase III clinical trials expected by end of 2026:  NEREUS™ (tradipitant) in vomiting in GLP-1,  VQW-765 in social anxiety disorder  HETLIOZ® (tasimelteon) in delayed sleep phase disorder  WASHINGTON, Aug. 5, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the second quarter ended June 30, 2026.  "We are pleased with the continued strong growth of Fanapt and the enthusiastic early response to NEREUS as it becomes available to patients.

Aug 05, 2026 12:01 PM • prnewswire.com
Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026

Vanda Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 5, 2026

Conference Call and Webcast to Follow WASHINGTON, July 29, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced it will release results for the second quarter 2026 on Wednesday, August 5, 2026, after the market closes.   Vanda will host a conference call at 4:30 PM ET on Wednesday, August 5, 2026, during which management will discuss the second quarter 2026 financial results and other corporate activities.

Jul 29, 2026 12:31 PM • prnewswire.com

Price Targets